Compare

EoCene Ltd. vs Allarity Therapeutics, Inc. vs Genelux Corp vs Marker Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearEoCene Ltd.
EOCN
Allarity Therapeutics, Inc.
ALLR
Genelux Corp
GNLX
Marker Therapeutics, Inc.
MRKR
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$320.0K$8.0K$3.55M
Revenue growth (YoY)n/an/a0.0%-46.2%
Gross marginn/an/an/an/a
Operating marginn/an/mn/m-363.5%
Net marginn/an/mn/m-343.0%
Net income$6.90M-$11.23M-$32.15M-$12.16M
EPS (Diluted)$2.39n/a-$0.86-$0.79
Operating cash flow-$6.32M-$14.82M-$25.27M-$12.01M
Free cash flown/a-$14.83M-$26.37Mn/a
Cash & equivalents$3.98M$14.69M$5.33M$16.07M
Total assets$18.63M$18.26M$19.03M$19.07M
Total liabilitiesn/a$8.43M$7.48M$2.27M
Shareholders' equity$15.78M$9.83M$11.54M$16.80M
Return on year-end equity43.7%-114.3%-278.5%-72.4%
Shares outstanding6.58M16.08M38.14M16.70M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearEoCene Ltd.Allarity Therapeutics, Inc.Genelux CorpMarker Therapeutics, Inc.
Latest$0
Ended 2020-12-31
$320.0K
Ended 2025-12-31
$8.0K
Ended 2025-12-31
$3.55M
Ended 2025-12-31
1 year earlier$0
Ended 2019-12-31
$0
Ended 2024-12-31
$8.0K
Ended 2024-12-31
$6.59M
Ended 2024-12-31
2 years earlier$2.04M
Ended 2018-12-31
n/a$170.0K
Ended 2023-12-31
$3.31M
Ended 2023-12-31
3 years earlier$1.08M
Ended 2017-12-31
n/a$11.07M
Ended 2022-12-31
$3.51M
Ended 2022-12-31
4 years earlier$467.0K
Ended 2016-12-31
n/an/a$1.24M
Ended 2021-12-31